Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NS19504 is a small-molecule, selective activator of large-conductance calcium-activated potassium (BK, KCa1.1, MaxiK) channels. Originally developed by NeuroSearch, the compound acts as a positive allosteric modulator of the BK channel, left-shifting its voltage activation curve and increasing potassium efflux. In preclinical studies, NS19504 has demonstrated the ability to relax bladder smooth muscle and reduce spontaneous phasic contractions, suggesting potential utility in bladder overactivity and urinary incontinence. Additionally, research has shown that NS19504-mediated BK channel activation exerts neuroprotective and anti-inflammatory effects in astrocytes, indicating potential therapeutic relevance in neuromyelitis optica spectrum disorders (NMOSD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NS19504.